Nicox SA (ALCOX.PA), an ophthalmology company, Thursday announced positive results from Denali Phase 3 study of of NCX 470 in patients with open-angle glaucoma or ocular hypertension.
The trial met its primary goal of non-inferiority in lowering intraocular pressure compared to the standard of care, latanoprost.
Based on these results, Nicox will receive a milestone payment of 5 million euros from Kowa. In July this year, the companies had signed an agreement granting Kowa exclusive rights to develop and sell NCX470.
Submission of a new drug application for NCX 470 in the U.S is expected in the first half of 2026.
"With a second Phase 3 trial demonstrating the necessary efficacy and safety profile for submission of New Drug Applications - NDAs - in both the United States and China, we are now moving forward towards potential recurrent NCX 470 royalty revenue from 2027 onwards. Our established partnerships with Kowa and Ocumension enable us to accelerate NDA preparations, whilst also allowing us to focus on potential future strategies for the company." said Gavin Spencer, Chief Executive Officer of Nicox.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.